CeleCor Therapeutics
Robert S. Hillman is a distinguished leader in the biomedical field, currently serving as Co-Founder, President, and CEO of CeleCor Therapeutics since July 2017, focusing on improving treatment for heart attack patients. Hillman's extensive experience includes influential roles such as Chief Technology Officer at Tem Systems, where the Rotem Sigma System was developed, and Co-Founder, President, and CEO at Accumetrics, which produced the VerifyNow System for platelet function diagnostics. In addition to consulting and advisory positions across various organizations, Hillman has contributed to the advancement of drug delivery systems as Chief Development Officer at Automedics. Hillman holds a BS in Biomedical Engineering from Stanford University, an SM in Chemical Engineering from MIT, and a PhD in Biomedical Engineering from ETH Zürich.
This person is not in any offices
CeleCor Therapeutics
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and laterdevelopment of heart failure.